Preliminary results from RECOVERY trial on the use of hydroxychloroquine in hospitalised patients with COVID-19

Content originally from Medical Research Council

The ‘RECOVERY’ trial has released preliminary results showing no effect on mortality from the use of hydroxychloroquine in patients admitted to hospital with COVID-19. The RECOVERY trial (which stands for ‘Randomised Evaluation of COVid-19 thERapY’) was funded by UKRI as part of the UKRI/DHSC/NIHR COVID-19 rapid research response.

To provide real-time information in the pandemic, the results have been announced as quickly as possible, so it should be noted that the findings have not yet been peer-reviewed and accepted in a journal.

A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in improving survival than the usual standard of hospital care which all patients will receive.

The RECOVERY trial is a large, randomised controlled trial of possible treatments for patients admitted to hospital with COVID-19. Over 11,000 patients have been randomised to several treatment arms, or no additional treatment – find out more on the RECOVERY website.

Read the full news article on the UKRI website.